- Current report filing (8-K)
March 16 2010 - 6:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of Earliest Event Reported):
March 16, 2010
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification
No.)
|
incorporation)
|
|
|
|
|
3450 Monte Villa Parkway, Suite 101
Bothell, WA 98021
(Address of principal executive offices)
(425) 354-5038
Registrants telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item
2.02. Results of Operations and
Financial Condition.
On March 16, 2010, AVI
BioPharma, Inc. (the Company) issued a press release announcing the
Companys financial results for the fourth fiscal quarter and fiscal year ended
December 31, 2009. A copy of the
press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this
Item 2.02, in Item 9.01 hereof and in Exhibit 99.1 shall not be
deemed to be filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such a filing.
Item
9.01. Financial Statements and Exhibits.
The following exhibit is
being furnished (not filed) herewith:
99.1
|
|
Press release, dated
March 16, 2010, entitled AVI BioPharma Announces Fourth Quarter and
Full Year 2009 Financial Results
|
2
SIGNATURES
Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, in the City of Bothell,
State of Washington, on March 16, 2010.
|
AVI
BioPharma, Inc.
|
|
|
|
By:
|
/s/ Leslie Hudson,
Ph.D.
|
|
|
|
|
|
Leslie Hudson, Ph.D.
|
|
|
President
and Chief Executive Officer
(Principal Operating Officer)
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press release, dated
March 16, 2010, entitled AVI BioPharma Announces Fourth Quarter and
Full Year 2009 Financial Results
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024